Zafgen, Inc.
Zafgen, Inc. is listed today as Larimar Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
3 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2020 | $80 M | Private placement after listing | $50 to $250 million | equity | SEC | |
| May 2020 | $82 M | Private placement after listing | $50 to $250 million | equity | SEC | |
| Nov 2012 | $22 M | No. 3 | $10 to $50 million | equity | SEC | |
| Jun 2011 | $6 M | No. 2 | $2 to $10 million | equity | SEC | |
| Feb 2010 | $8 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Zafgen, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2020).
SEC Form D · Jun 2020
The industry group it chose in its notices: Other Health Care.
SEC Form D · Jun 2020
That is all the official record says: Zafgen, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Zafgen, Inc. are on record.
Investors#
6 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Atlas Venture Associates VII, Inc. | Venture capital | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Atlas Venture Associates VII, L.P. | Venture capital | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Atlas Venture Fund VII L.P. | Venture capital | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Third Rock Ventures GP, L.P. | Venture capital | not stated | not stated | Held Series B, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Third Rock Ventures LP | Venture capital | not stated | not stated | Held Series B, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| TRV GP, LLC | Other | not stated | not stated | Held Series B, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 6 investors.
Largest shareholders today
Institutions holding Larimar Therapeutics, Inc. shares, as of Sep 30, 2026.
- Deerfield Management Company, L.P.$114 M34.28%
- Blue Owl Capital Holdings LP$32 M9.55%
- RTW Investments, LP$19 M5.60%
- BlackRock, Inc.$18 M5.55%
- Defilade Capital Management, L.P.$16 M4.75%
- Driehaus Capital Management LLC$10 M3.01%
- Vanguard Capital Management LLC$10 M2.86%
- Goldman Sachs Group Inc$9 M2.86%
- AQR Capital Management LLC$7 M2.16%
- Marshall Wace, LLP$7 M2.11%
- DAFNA Capital Management LLC$6 M1.82%
- Bank Of America Corp /de/$6 M1.80%
- AIGH Capital Management LLC$6 M1.78%
- Geode Capital Management, LLC$6 M1.68%
- Millennium Management LLC$5 M1.61%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Carole Ben Maimon, MD | President and CEO | Jun 2020 |
| Michael Celano | Chief Financial Officer | Jun 2020 |
| Dennis D. Kim | Executive officer | Dec 2012 |
| Matthias Jaffe | Executive officer | Dec 2012 |
| Mitchell S. Bloom | Executive officer | Dec 2012 |
| Thomas Hughes | Executive officer | Dec 2012 |
| Carole Ben Maimon, MD | President and CEO | Jun 2020 |
| Frank E. Thomas | Director | Jun 2020 |
| Jonathan Leff | Director | Jun 2020 |
| Joseph Truitt | Director | Jun 2020 |
| Peter Barrett | Director | Jun 2020 |
| Thomas Hamilton | Director | Jun 2020 |
| Thomas O. Daniel | Director | Jun 2020 |
| Avi S. Goldberg | Director | Dec 2012 |
| Bruce S. Booth | Director | Dec 2012 |
| Frances S. Heller | Director | Dec 2012 |
| Kevin S. Starr | Director | Dec 2012 |
| Lou S. Tartaglia | Director | Dec 2012 |
| Peter S. Barrett | Director | Dec 2012 |
| Thomas Hughes | Director | Dec 2012 |
| Louis S. Tartaglia | Director | Jul 2011 |
| Dr. Liam S. Ratcliffe | Director | Mar 2010 |
| Ari S. Goldberg | Director | Mar 2010 |
About
Company in Boston, United States.
Went public since 2014. Its SEC number is that of a company listed on a stock exchange.